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Role of Chemically Induced Cell Proliferation
in Carcinogenesis and Its Use in Health Risk
Assessment
by Robert G. Croy
There is much interest in incorporating knowledge ofbiological mechanisms of carcinogene-
sis into assessments of health risks to humans posed by chemicals in the environment. Debate
over the soundness ofusing data from animal bioassays conducted at minimally toxic doses or
fractions thereoffor predicting cancer risks to humans exposed to much lower doses has stimu-
lated interest in the question of whether genotoxic or mitotic effects predominate in chemical
carcinogenesis. Cell division plays a key role at each stage in the evolution of cancer, and it is
well documented that increased rates of cell proliferation can escalate the risk of malignancy.
This article examines the current understanding of both mechanisms by which chemicals pro-
voke cell proliferation and the contribution of various kinetic patterns of cell proliferation to
carcinogenesis.
Introduction
Malignant transformation is a complex process
involving multiple genetic changes that result in
uncontrolled patterns of cell growth. Dividing cells are
at increased risk for both spontaneous genetic damage
as well as that induced by genotoxic agents. Thus,
chemical or physical agents that cause damage to DNA
and/or increase the rate of cell division also increase
the probability of the occurrence of important genetic
changes leading to cancer.
The circumstances in which genotoxic or mitogenic
activities predominate in the cancer process has
recently stimulated debate concerning the soundness
of using data from high-dose animal bioassays for the
purpose of predicting cancer risk to humans. In the
absence ofmechanistic information, the EPA and other
regulatory agencies currently follow the conservative
assumption that cancer incidence decreases (or
increases) linearly with dose throughout the entire
range ofpossible exposures (1). There are, however, an
increasing number of examples of nonlinear dose-
response relationships in which the slope of the dose-
response curve was found to change dramatically at
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higher doses (2). Changes in a number of factors
including pharmacokinetics, metabolism, and toxic
effects have been associated with such dose-related
changes in cancer potency. Chemically induced cell
proliferation is one such factor that is of particular
interest with regard to determination of cancer poten-
cy relationships for chemicals that have genotoxic
effects, as well as so-called nongenotoxic chemicals
(those not directly reactive with DNA) for which a
direct cause and effect relationship with genetic
change is lacking.
There is conflicting evidence as to whether chemical-
ly induced cell proliferation per se can increase the risk
of neoplastic transformation. One view contends that
an increased rate of cell division is primarily responsi-
ble for the carcinogenic effects of many nongenotoxic
chemicals. Ames and Gold (3), for example, have sug-
gested that many chemicals observed to cause tumors
in rodents act indirectly by stimulating cell prolifera-
tion that, in turn, increases both the likelihood that
endogenous DNA damage will produce mutations and
the number of cells at risk for progressive changes in
gene expression that lead to malignancy. On the other
hand, it has been pointed out that hematopoietic tis-
sues and the small intestine, both of which have high
rates of cell proliferation, have a low incidence of
tumors (4). This apparent conflict indicates the frag-
mentary state of knowledge concerning how different
patterns of cell growth and death in various tissues
influence the carcinogenic process.
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induced cell proliferation in assessing the carcinogenic-
ity of certain chemicals. In examining this broad sub-
ject, my objective was not to provide a comprehensive
review but rather to highlight areas ofuncertainty and
indicate where generalizations are not supported by
adequate data. A brief review of the basic role of cell
proliferation in carcinogenesis is given. I then describe
bioassay results for several chemicals in which chemi-
cally induced cell proliferation has been clearly associ-
ated with a nonlinear relationship between dose and
tumor formation. In addition, some examples ofmolec-
ular mechanisms by which chemicals can produce mito-
toxic responses will be discussed. Finally, I will consid-
er what information about cell proliferation would be
necessary to enable its prudent use in cancer potency
estimates. Where necessary, topics that require fur-
ther investigation either in the scientific literature or
through experimental studies have been indicated.
Role of Cell Proliferation in
Carcinogenesis
Chemical carcinogenesis has been empirically divid-
ed into sequential steps or stages in which cells pro-
gress from normal to premalignant foci to localized
tumors and to invasive, malignant growths (5). There
is little disagreement that cell proliferation plays a key
role in each stage oftumor formation. The first step in
the sequence ofevents that transforms a normal cell to
malignancy has been termed initiation. Initiated cells
have been permanently altered so as to have the
potential to express the malignant phenotype.
Additional steps (stages) in tumor formation have been
termed "promotion" and "progression." Promotion
involves reversible changes in cell populations within a
tissue that place initiated cells at increased risk for
further genetic changes. Progression occurs when
changes in the cell's genetic program produce irre-
versible characteristics ofthe malignant phenotype.
More than one genetic change may be required to
complete each stage in the carcinogenic process. In
human colon carcinogenesis, specific genetic alter-
ations have been related to different stages in the evo-
lution of malignancy (6). Such genetic changes could
not occur and would not be expressed in the absence of
DNA replication and cell division. It seems likely that
a variety of treatments that accelerate the carcino-
genic process do so through their ability to increase
cell division. Treatments such as partial hepatectomy
that induce cell proliferation greatly enhance the
appearance of preneoplastic foci and hepatocellular
carcinomas in the livers of rats treated with carcino-
genic chemicals (7).
The etiology and mechanisms of genetic damage
found in malignant cells is unknown. There are several
ways in which cell proliferation can in principle aid the
diverse processes that increase the amount of genetic
damage in cells. Replication ofdamaged DNA increas-
es the probability that chemically damaged bases in
DNA will result in mutations or other genetic fla
Errors in the replication of undamaged DNA can a.
produce various kinds of genetic alterations. Thu
chemicals that do not directly damage DNA but ar
able to induce cell division may also induce genetit
changes, some ofwhich may result in mutations impor-
tant to cancer. In human somatic cells, point muta-
tions, deletions, and insertions occur spontaneously
(8,9). Such random errors are thought to account for
the incidence ofspontaneously initiated cells in the liv-
ers and other organs of control animals. It has been
suggested that hyperplasia per se can increase the
probability of genetic change by increasing the likeli-
hood of mutations arising from normal DNA replica-
tion processes or the conversion of DNA lesions pro-
duced by oxygen radicals formed endogenously to
mutations (3,10). Various estimates have been made of
the amounts of spontaneous DNA damage suffered by
rats and humans (11,12), but to date, there have been
no estimates of the frequency of mutations caused by
such DNA damage. Thus, the significance of DNA
damage resulting from endogenous reactants such as
oxygen radicals remains speculative.
For many nongenotoxic or weakly genotoxic chemi-
cals, the ability to induce cell proliferation is believed
to be a critical factor for the development of tumors in
experimental animals (13,14). Some evidence suggests,
however, that chemicals that accelerate the promotion
and progression stages of carcinogenesis do more than
simply increase the rate of cell proliferation. Various
phorbol esters, for example, reportedly block differen-
tiation ofkeratinocytes (15) and can indirectly produce
physical damage to cellular DNA (16,17). In the rat
liver, phenobarbital prevents the death of cells in
altered foci of hepatocytes (18). Thus, although the
ability to induce cell proliferation appears to be neces-
sary for tumor development, it may not be sufficient.
There are, in fact, several reports (discussed below) of
animal experiments in which increased cell prolifera-
tion inhibited or had no observable effect on tumor for-
mation.
Despite these exceptions, the ability of chemicals to
increase the rate of cell proliferation in tissues has
emerged as an important factor that can influence esti-
mates of carcinogenic potencies. Furthermore, accu-
mulating epidemiological evidence points to increased
cell division as an important factor in the pathogenesis
of many human cancers (19). We can infer from this
evidence that consideration of genotoxic effects alone
will not provide an accurate assessment of cancer risk
to humans from chemical exposure. At present, howev-
er, results ofrodent bioassay experiments provide the
best evidence against the existence of simple linear
dose-response relationships for chemical carcinogens.
The following section briefly discusses several experi-
ments in rodents in which proliferation of cells in tar-
get tissues has dramatically affected the cancer dose-
response relationship.
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Nonlinear Dose-Response
Relationships for Carcinogens
Several lines ofinvestigation provide persuasive evi-
dence that chemically induced cell proliferation can
determine the shape of the dose-response curve for
chemical carcinogens. Because more than one indepen-
dent mutation is believed to be required for most can-
cers, genotoxic effects alone could produce a nonlinear
dose-response relationship. In several cases, however,
such nonlinear relationships for genotoxic chemicals
lead to the inference that effects other than direct dam-
age to DNA can govern cancer potency. The inference
has been substantiated in several cases by determining
both the concentration of promutagenic DNA adducts
and the extent of cell proliferation in the target organ
as a function of dose. Investigators of nongenotoxic
chemicals found several dose-response relationships in
rodents that display apparent no-effect levels. These
agents apparently act through diverse means to stimu-
late cell proliferation. In some cases cytotoxicity has
been implicated in the tumorigenic abilities of these
chemicals, and their effect on target tissues is obvious.
The actions of other chemicals may be more subtle and
have been attributed to their ability to subvert specific
receptors that regulate cell growth. Such is apparently
the case for the tumor-promoting phorbol esters that
activate protein kinase C.
A limited number of dose-response relationships for
carcinogens have been investigated using doses much
lower than those customarily used in rodent bioassays.
Both linear and nonlinear relationships between dose
and rate of tumor formation have been observed for
different chemicals. In some studies, these distinct
types of relationships have been observed simultane-
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ously in different tissues of the same species. Figure 1
shows that different dose relationships were observed
for liver and bladder tumors in female BALB/c mice
fed 2-acetylaminofluoreiie (AAF) in the diet for 24
months (20,21). The incidence of liver cancer showed a
linear relationship with dietary concentration of AAF,
whereas a sharp increase occurred in the slope of the
dose-response curve for bladder tumors at approxi-
mately 60 ppm. AAF is a potent genotoxin, which
would be expected to be the primary basis for its
tumorigenic effects. But, as discussed below, in some
circumstances the likelihood of bladder cancer from
AAF appears to be primarily determined by its cyto-
toxic effects.
Experimental bladder carcinogenesis has provided
several examples for which hyperplasia was associated
with nonlinear dose-response relationships. Chronic
exposures to the genotoxic chemicals 2-acetylaminoflu-
orene (AAF) and N-[-4-(5-nitro-2-furyl)-thiazoyl]for-
mamide (FANFT) have been shown to produce blad-
der cancer in mice (22,23). In the case of AAF, a sharp
increase in bladder tumors (see Fig. 1) was observed in
animals receiving 60 ppm AAF in the diet. However,
the concentration ofAAF adducts in bladder DNA was
found to be a linear function of dose over a range of
5-150 ppm AAF in the diet (24). The amount ofpromu-
tagenic DNA damage was related linearly with dose,
but tumor formation was not. With both AAF and
FANFT, the sharp increase in the dose response for
tumor formation occurred at doses that resulted in
toxic and proliferative effects on the bladder epitheli-
um. Littlefield et al. (22) reported that although a
dietary level of30 ppm AAF did not produce hyperpla-
sia in the bladder epithelium, levels of 60 ppm did.
Thus, the observed bladder-tumor response was more
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FIGURE 1. Relationship between dose of2-acetylaminofluorene fed to female BALB/c mice and prevalence ofliver and bladder carcinomas after
24 months (20,21).
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clearly correlated with the ability ofAAF to cause tis-
sue hyperplasia than with the risk of genetic damage.
As a consequence, dietary levels below those that
cause hyperplasia in the bladder epithelium would be
much less likely to cause bladder tumors than would be
predicted by simple extrapolation ofthe dose response
at levels ofAAF >60 ppm (25).
In contrast to the bladder's response to AAF, as
shown in Figure 1, AAF-induced liver tumors in mice
demonstrated a linear relationship with dietary con-
centrations between 30 and 150 ppm (21). A number of
explanations have been proposed for divergence in
tumor responses to AAF between the liver and blad-
der. These include pharmacokinetic and metabolic dif-
ferences as well as the number of genetic alterations
necessary for the malignant transformation of the dif-
ferent cell types. Biochemical evidence and mathemati-
cal models, however, have indicated that tissue dissim-
ilarity in toxic and proliferative responses to AAF
provide the best explanation for AAF's distinct dose-
response relationships in the liver and bladder. Based
on the absence of liver enlargement, Cohen and
Ellwein (26) have suggested that 30-150 ppm AAF in
the diet did not increase the rate ofliver cell prolifera-
tion above background. On this evidence, they have
inferred that AAF's only effect on the liver was an
increase in the number ofinitiated cells. In the absence
of cytotoxic effects, additional genetic alterations
needed for the malignant transformation of initiated
cells depended on normal rates ofproliferation, which,
although low in the liver, were effective because a
large number of such cells produced by AAF were at
risk. In contrast, similar doses produced few initiated
cells in the bladder where endogenous rates of cell
division were too low to increase the probability of
tumor formation.
AAF does, in fact, produce a nonlinear tumor
response in the liver at doses greater than used in the
study described above. At higher dietary concentra-
tions, AAF produces overtly cytotoxic effects in the
liver, resulting in compensatory proliferation and a
sharp increase in the rate of tumor formation (27).
Perhaps other chemicals would show the same pattern
of tumor response if tested over such a large range of
doses.
Peto et al. (28) examined the incidence ofliver cancer
in rats exposed to drinking water containing 0.4-40 ppm
diethylnitrosamine (DEN) and found a nonlinear
response. A sharp increase in the cancer potency of
DEN for liver tumors occurred at approximately
4 ppm DEN. The increased cancer potency of DEN
concentrations greater than 4 ppm was not due to
enhanced genotoxic effects. Investigations by Bou-
cheron et al. (29) found that continuous exposure to
DEN resulted in the concentration-dependent accumu-
lation of promutagenic adducts in DNA over a similar
range ofdrinking water concentrations. Further inves-
tigations by Deal et al. (30) found that exposure to
drinking water containing 4 ppm or greater DEN
resulted in cytotoxic effects and increased cell prolifer-
ation in the target tissue. At 4 ppm DEN there was a 3-
fold increase in hepatocyte replication after 10 weeks;
100 ppm DEN led to a 15-fold increase. They suggested
that the increased rate of hepatocyte proliferation was
a major factor relating the nonlinear tumor response to
the linear accumulation ofDNA adducts.
These experimental findings indicate that genotoxic
carcinogens are likely to display their most potent
effects in the range of doses for which both genotoxic
and proliferative effects coincide. Outside this range
tumor response will be diminished. At high doses,
lethal effects can result in the destruction of initiated
cells and a reduction in the predicted incidence of
tumors. Low doses that do not increase normal rates of
cell proliferation will not provide greater opportunity
for genetic changes required to advance initiated cells
through the later stages of neoplasia. In this latter
case, disturbances in the control of cell proliferation
may have a crucial role in tumor development.
Nonlinear dose-response relationships have also
been observed for carcinogenic substances that do not
directly damage DNA. Unleaded gasoline produced
kidney tumors in male rats at doses that cause epithe-
lial cell death and regenerative proliferation in the
proximal tubule-doses that did not cause cell injury
did not cause tumors (31). Bladder tumorigenesis in
rats by sodium saccharin requires doses sufficiently
high to form urinary calculi that result in focal hyper-
plasia (32). Dose-related effects have also been docu-
mented for tumor promoters on mouse skin. Verma
and Boutwell (33) reported that repeated application of
less than 1.0 nmole of 12-O-tetradecanoylphorbol-13-
acetate (TPA) did not elicit tumors on mice previously
initiated with 7,12-dimethylbenz[a]anthracene (DMBA).
The available evidence has been interpreted by some
to support the inference that practical thresholds exist
for carcinogenesis by nongenotoxic chemicals, but this
proposition is not universally accepted.
Sharp changes are likely to exist in the slope of the
dose-response relationships for many chemical carcino-
gens. If such is the case, there is considerable uncer-
tainty in the use ofmethods that employ linear extrap-
olations to predict health effects well beyond the range
ofexperimental data. At present, only descriptive ani-
mal studies can answer the question of how the car-
cinogenic potency of a chemical may change as a func-
tion of dose. This approach is, however, an impractical
one, since the expense of rodent bioassays that use
large numbers of animals and a wide range of doses is
prohibitive. A more rational strategy is to acquire an
understanding of the basic mechanisms that can alter
dose-response relationships. It should then be possible
to determine how and under what circumstances
chemicals that affect particular biochemical pathways
involved in growth regulation influence tumor
response. Such knowledge also opens the door for the
development of practical biochemical tests to identify
chemicals that have such activities.
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Mechanisms of Chemically Induced
Cell Proliferation
Progressive changes in the regulation of cell growth
are fundamental to the evolution of cancer. Up till now,
molecular studies of the cancer process have focused
primarily on irreversible genetic changes to key genes
that regulate growth and development. It has become
increasingly clear, however, that abnormalities in tis-
sue growth and development induced by chemical
injury may augment the rate of genetic damage and
the development of malignancies. Unfortunately,
although there are many descriptive studies of the
toxic effects ofchemicals on certain tissues such as the
liver, there is only sketchy information at the molecu-
lar level concerning the mechanisms by which cell
growth and development are affected by acute or
chronic cell injury.
Figure 2 shows a paradigm indicating various mech-
anisms by which chemicals could increase the rate of
cell proliferation in tissues. The means by which chem-
icals affect growth regulatory pathways can be divid-
ed into two general categories: those that act indirect-
ly as a consequence of cytotoxic and/or inflammatory
effects and those that act directly by interaction with
cellular receptors that produce biochemical changes
triggering growth.
The generality ofthe schemes presented in Figure 2
has not been fully explored. It is unlikely that a single
pathway is responsible for a chemical's proliferative
effects. Evidence in vitro and in vivo indicates that cell
growth and behavior are determined by combinations
of interacting stimuli. Cytotoxic damage and tissue
responses vary with dose and frequency of exposure.
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FIGURE 2. Pathways by which chemicals can stimulate cell prolifera-
tion in tissues.
The molecular basis for proliferative responses to
acute or chronic cell injury are also likely to vary with
dose. For example, inflammatory mediators are likely
to be incriminated in the regenerative proliferation
resulting from necrotic doses of CC14 that produce an
intense inflammatory response, whereas local produc-
tion of cell-specific factors may be primarily responsi-
ble for cell division at much lower doses not resulting
in inflammation. How some chemicals produce their
proliferative effects is discussed below.
Proliferative Responses to Cytotoxic
Damage
Rodent liver has received the most attention with
respect to the identity oftissue-specific factors involved
in proliferative response to injury. In the adult liver,
hepatocytes rarely divide except in response to injury
or xenobiotics. The identity of polypeptide factors
that mediate liver regeneration is an active area of
research. Several groups of investigators have identi-
fied related polypeptide growth factors that may be
involved in regenerative growth of the liver after par-
tial hepatectomy or after injury from toxic chemicals.
This factor, which has been referred to as hepatocyte
growth factor (34), hepatopoietin A (35), or hepa-
totropin (36) promotes DNA synthesis and cell division
in primary cultures ofrat hepatocytes.
The concentration of hepatocyte growth factor
(HGF) has been found to increase dramatically in the
liver after physical injury and hepatitis caused by
infectious agents or chemicals. HGF has been identi-
fied in the plasma of patients with fulminant hepatic
failure (37). It has also been found to be markedly
increased in the livers of rats that suffered necrotic
injury resulting from treatment with CC14 (38). After
CC14 injury, there is a rapid rise in the level of HGF
transcript in nonparenchymal cells (principally Kupffer
cells), but not in hepatocytes (39). Further evidence of
the role of HGF in liver regeneration has been provid-
ed by Higuchi et al. (40), who recently identified a
receptor on the surface of rat hepatocytes that binds
HGF with high affinity. Rapid disappearance (down-
regulation) of HGF receptors from the cell membrane
as a result ofinternalization ofHGF-receptor complex-
es occurred in response to partial hepatectomy or
CCl4-induced hepatitis. This suggests that Kupffer
cells are crucial to the liver's ability to replace cells
that are damaged or lost.
The discovery of HGF stimulated speculation about
the existence ofa variety oftissue-specific growth fac-
tors. Further investigations, however, have evidenced
a more general role for HGF in proliferative responses
in extrahepatic tissues. Gherardi and Stoker (41) have
reported that the receptor for HGF is the product of
the protooncogene c-met. Studies on the expression of
c-met have identified its transcript in a number of
human tissues including kidney, thyroid, liver, and
stomach (42). High concentrations of HGF have been
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also been observed in extrahepatic tissues (43). These
findings indicated a role ofHGF and its receptor in the
regulation ofgrowth and regeneration ofthe liver and
possibly several other tissues. HGF, however, is not
the only growth regulator forthe liver or other organs.
A variety ofevidence indicates that tissue homeostasis
is maintained by the collaborative effects of polypep-
tide hormones.
Neither does growth regulation hinge exclusively on
growth factors. Growth inhibitors play an important
role, especially in vivo where cells rarely divide at
maximum rates. These findings suggest several ways
in which chemicals can affect the rate of cell prolifera-
tion: (a) activation ofpositive factors such as epidermal
growth factor (EGF) or HGF or (b) inactivation ofneg-
ative growth factors such as transforming growth fac-
tor-P (TGF-P). It can be inferred that the proliferative
response to cytotoxic injury is likely determined not
by a single growth factor but by the combined effects
of positive and negative regulators. This inference is
supported by the presence ofboth types of regulators
in various tissues and their effects on cells in vitro.
Combinations of polypeptide growth factors have
been observed to either stimulate or inhibit the prolif-
eration ofhepatocytes in culture (44). EGF and TGF-a
have been demonstrated to be potent mitogens for
hepatocytes (45,46). TGF-,3 reportedly inhibits the
growth ofhepatocytes and other cell types both in vivo
and in vitro (47). Combinations of growth factors are
also implicated in the regenerative growth of the skin
after injury by toxic chemicals. Akhurst et al. (48) have
reported evidence of localized production of TGF-1 in
stimulated mouse epidermis. Keratinocytes also both
produce and respond to a number of growth factors
including the cytokines interleukin 6 (IL-6) and inter-
leukin l(IL-1) as well as transforming growth factor
a(TGF-a). High levels of both IL-6 and TGF-a have
been found in activation of epidermal cell growth in
psoriatic skin (49,50).
The repeated observation ofincreased expression of
several polypeptide hormones in injured tissues sug-
gests that most may have a broad range of target tis-
sues. Cytokines released from immune cells are likely
to be important mediators of tissue response to acute
or chronic injury of many tissues. Increased levels of
IL-6 have been found in a variety of tissues in
response to infection or injury (51). Likewise because
oftheir wide tissue distribution, TGF-,Bs may be signif-
icant in the coordination of growth responses in many
tissues. Unfortunately, there is a general absence of
information about the mechanisms by which cellular
injury induces the synthesis or triggers the release of
TGF-f or other polypeptide factors that mediate
inflammatory and hyperplastic responses.
Continued diversification of the list of polypeptide
growth factors seems likely. A recent review by Cross
and Dexter (52) discusses the influence of stimulatory
and inhibitory factors in the growth and development
of various tissues. This broadening spectrum makes
understanding the molecular bases of chemically
induced cell proliferation difficult. Although the num-
ber of these factors that stimulate cells in vitro is
increasing, there may be only a limited number that
make varied contributions to regenerative cell growth
in vivo. Given adequate information about these key factors, we should be able to predict cellular responses
in vivo.
Proliferative Response in the Absence
ofCytotoxic Damage
Not all chemicals that increase the rate of cell divi-
sion in tissues do so through responses to cell injury.
Chemicals can also subvert the biochemical circuitry
that regulates cell growth. They can do so by activa-
tion of cellular molecules that provoke biochemical
changes within the cell. In some cases, this can be
accomplished by low levels of a chemical with a high
affinity for its cellular target. In others, relatively
large doses are required, perhaps to displace an
endogenous ligand that has greater affinity. Regard-
less, prolonged exposure to such chemicals is frequent-
ly required, presumably to override the cell's fail-safe
mechanism that prevents accidental triggering of its
mitotic program. Consequently, evidence suggests
that chemicals that are rapidly metabolized and elimi-
nated are generally ineffective mitogens.
Pharmacologic concentrations of chemicals that are
members of a diverse group that includes hypolipidem-
ic drugs, such as clofibrate, stimulate peroxisome pro-
liferation and hyperplasia in the liver. Evidence sug-
gests that cellular responses to these chemicals are
mediated through their interaction with an intracellu-
lar receptor structurally related to those ofthe steroid
hormone family (53). Interestingly, the proliferative
response to some ofthese chemicals is transient, while
others produce a sustained elevation of cell prolifera-
tion. Carcinogenic potency shows a positive association
with the ability of several peroxisome proliferators to
produce a sustained proliferative response (54).
However, for other chemicals in this group, including
clofibric acid and nafenopin, a sustained proliferative
response did not appear to be a factor in hepatocar-
cinogenesis (55), suggesting the involvement of other
factors. If receptor activation is the key to prolifera-
tive responses to peroxisome proliferators, further
studies at the molecular level will provide the opportu-
nity to determine how sustained or transient patterns
of liver cell hyperplasia are determined for these
chemicals and theirrole in the malignant process.
Phenobarbital (PB) is another example of a nontoxic
chemical that stimulates liver cell proliferation and is
an effective promoter of initiated cells. As is the case
with some of the peroxisome proliferators, PB pro-
duces a transient increase in mitosis in liver cells.
However, persistent effects of PB have been reported
on mitotic rates ofpreneoplastic cells. Analysis ofPB's
effects on proliferation of normal hypatocytes and
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those in preneoplastic foci revealed an increased mitot-
ic rate in these foci (56). The results of further experi-
ments suggested that PB's ability to decrease the rate
of cell death (apoptosis) was primarily responsible for
increased cell proliferation in foci (18,57). Thus, PB's
effects on the rates of birth and death of normal and
preneoplastic liver cells result in the preferential
growth and accumulation of cells that are at greater
risk for tumorigenic transformation. There is genetic
evidence that PB interacts with an intracellular recep-
tor, but it has been difficult to obtain biochemical evi-
dence to confirm the receptor's existence.
Interaction with intracellular molecules underlies
the ability of several chemicals to stimulate cell divi-
sion and fuel the cancer process. Activation of the
estrogen receptor seems to mediate the liver's mitotic
response to estrogenic compounds. Tumor promoters
such as 17 a-ethinylestradiol interact with intracellular
receptors resulting in responses similar to those trig-
gered by endogenous hormones (58,59). The basis of
dioxin's ability to induce epidermal hyperplasia, among
other effects, is its interaction with the Ah receptor
(60). Similarly, TPA and related phorbol esters that
are effective tumor promoters bind to and activate
protein kinase C (PKC), resulting in the stimulation of
signal transduction pathways (61).
How can we develop a better understanding of the
ways in which chemicals stimulate cell division? The
paradigm that both toxic and nontoxic doses of chemi-
cals cause cell proliferation through diverse receptor-
mediated processes suggests a strategy for developing
an understanding ofboth the qualitative and quantita-
tive aspects of this response. For cytotoxic chemicals,
focus should be on identification ofgrowth factors that
mediate tissue reactions such as hyperplasia. Under-
standing the regulation oftheir synthesis, release, and
degradation, as well as the regulation of their recep-
tors, is key to predicting cellular response. This know-
ledge could provide a means ofidentifying the types of
chemical damage to cells that are capable of causing
proliferative responses. For example, the identification
and isolation of the gene for HGF, discussed above,
opens the way to investigate the types of cellular
injury that provoke increased levels of HGF and/or its
receptor on target cells.
One means by which cells recognize and respond to
injury is through the synthesis ofa small group ofpro-
teins that have been called heat shock proteins (HSP).
The synthesis of members of this family of proteins is
activated under conditions of stress including that
induced by elevated temperature or damage to DNA
or proteins (62). There are a number ofreasons to sus-
pect a link between the induction of HSP and stress-
induced cell proliferation. The evidence forthis connec-
tion has recently been reviewed by Pechan (63). An
intriguing finding is that one of the two prominent 70
kD HSPs is induced just before S phase when quies-
cent serum-starved cells are fed again (64). The HSP-
70 protein has also been implicated in cellular respons-
es to peroxisome proliferators (65). In relation to cyto-
toxic chemicals, it has been reported that the
antitumor drug 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU), which carbamoylates proteins and nucleic
acids, selectively induced the synthesis of the human
heat shock and stress-induced genes HSP-90 and HSP-
70 (66).
The biochemical activities of HSPs are well suited
for diverse roles in the assembly and function of cellu-
lar molecules. The ability ofvarious HSPs to recognize
denatured or abnormally folded proteins is believed to
be essential for induction of both stress responses and
a number of essential roles of HSP proteins in cellular
processes that occur during normal growth and devel-
opment (67). Although a number of specific roles for
HSPs in cell proliferation have been proposed, none is
certain as yet. It is certain, however, that continued
investigation of the HSPs will uncover more diverse
roles for these proteins in normal and injured cells.
Even without knowing the precise mechanisms, any
understanding that we gain will contribute to our abili-
ty to evaluate the proliferative potential of unknown
chemicals, given the types of cytotoxic damage they
can inflict.
Patterns of Chemically Induced Cell
Proliferation Determine
Carcinogenic Response
Increased rates of cell division do not always
enhance tumor formation. One should remember that
while hematopoietic cells have a high rate of division,
cancers of these cells are relatively rare in humans.
This may be because the majority of cell divisions do
not take place in hematopoietic stem cells, but in cells
with relatively brief life spans and are eventually lost
to the host. In experimental chemical carcinogenesis,
there are a number of examples where cell prolifera-
tion ultimately either suppressed tumor development
or had no effect. The following discussion reviews sev-
eral such studies that point to the need for a better
understanding of the dynamic interactions between
cell populations and their influences on carcinogenesis.
Numerous descriptive studies have documented dif-
ferent kinetic patterns of cell growth and death in tis-
sues exposed to toxic substances. The term "hyperpla-
sia" has been used to describe a wide range of
regenerative responses to toxic and physical agents as
well as reversible changes that result directly from
mitogenic substances. Hyperplasia can result in an
increase in both the cell number and size of the tissue
or, ifthe tissue has suffered loss ofcells, restoration of
the normal cell number and tissue architecture. Both
types of response produced by chemical and physical
agents can enhance the carcinogenic process-to do
so, however, a sustained increase in cell number is nec-
essary. The dynamics of hyperplasia depend on the
biological activities of the chemical as well as the fre-
295R. G. CROY
quency of exposure and dose. In some circumstances,
withdrawal of mitotic agents results in elimination of
cells and return of the tissue to its normal size.
Elimination of excess cells takes place by a process of
controlled cell death termed "apoptosis". The process
of apoptosis can have an adverse influence on tumor
formation.
In the liver, various treatments that induce regen-
erative hyperplasia are effective in enhancing the
neoplastic process, whereas others that induce a tem-
porary increase in cell number are not. Partial hepa-
tectomy or treatments with hepatotoxic chemicals that
induce strong proliferative responses result in acceler-
ated growth and clonal expansion of initiated cells,
placing them at increased risk of further genetic
change. In contrast, as the results of several experi-
ments described below indicate, treatments that pro-
duce repeated patterns of cell growth and death are
typically ineffective in promotingtumor formation.
Columbano et al. (68-70) found that intermittent
administration ofany ofthe three liver mitogens ethyl-
ene dibromide (EDB), lead nitrate, and nafenopin did
not promote DEN-initiated hepatocytes. They observed
no increase in the number of preneoplastic foci in ani-
mals that had received four consecutive treatments of
these chemicals in which four daily intragastric doses
were given every 20 days (70). The same chemicals
were also found to be ineffective during the initiation
stage of the carcinogenic process when given just
before a small dose ofagenotoxic chemical (69). In con-
trast, intermittent treatment with CC14 or partial
hepatectomy, which induced comparable levels of
DNA replication and mitosis, produced numerous pre-
neoplastic foci in the livers ofDEN-treated rats (69).
In explaining their negative findings for the three
mitogens, Columbano et al. (69,70) suggested that any
initiated cells formed during the mitotic response were
eliminated when the chemical was withdrawn. Instead
of a sustained increased in cell number, the chemical
treatments resulted in cycles of cell growth and death
in the liver. An increase in liver size (increased
liver/body weight ratio) occurred during and shortly
after administration of the four daily intragastric
doses. In the interim periods between these treat-
ments, liver size returned to normal through apoptosis
(68,71). Thus, initiated or preneoplastic cells formed
during the liver's mitotic response were likely elimi-
nated. In contrast, initiated cells produced during tis-
sue regeneration in response to acute or chronic injury
(CC14, partial hepatectomy) were not eliminated
because these initiated cells replaced lost cells. In this
case, initiated cells were at risk for further genetic
changes that can result in cancerous growth.
Xu et al. (72), in a series ofexperiments with PB, have
reported results similar to those found by Columbano
et al. (68-70). If administered intermittently, PB was
unable to increase the number of preneoplastic foci
in livers of animals previously treated with DEN.
Continuous administration ofPB, however, resulted in
a large increase in the number of preneoplastic foci.
These findings suggest that the ability ofa chemical to
function as a promoter in liver carcinogenesis is highly
dependent on the dosing regimen used and the kinetic
pattern ofcell proliferation.
Different patterns of hyperplasia also have distinct
effects on tumor formation in mouse skin and the rat
forestomach. According to Argyris (73), the ability ofa
treatment to elicit a sustained regenerative hyperpla-
sia is decisive in determining its effectiveness as a
tumor promoter. Efficient tumor promoting sub-
stances such as TPA produce a persistent hyperplastic
response with continued treatment. In contrast, acetic
acid and mezerine, which are ineffective promoters,
initially produce an epidermal hyperplasia that is com-
parable to that seen with TPA, but repeated treatment
results in a diminution ofresponse and reduced mitotic
activity. These results indicate that proliferative
response alone may give a false indication of a chemi-
cal's potential to act as a tumor promoter in mouse
skin.
The contrasting effects of the two phorbol esters
TPA and retinoylphorbol acetate (RPA) on mouse skin
tumorigenesis provide another example ofthe complex
relationship between cell proliferation and carcinogen-
esis in mouse skin (74). Both TPA and RPA induce
hyperplasia, but RPA is ineffective in promoting the
early stages ofmalignant transformation in NMRI and
CD-1 strains of mice. In Sencar mice, however, RPA
was found to be an effective tumor promoter of skin
tumors (75). Thus, there are strain-specific differences
in response to these compounds, the basis of which is
not understood.
In the rat forestomach, the ability of chemicals to
cause irritation and resultant hyperplasia of the
epithelium has been clearly associated with the tissue's
potential tumorigenic response. A number ofchemicals
without demonstrable genotoxic activity, including
butylated hydroxyanisole (BHA), propionic acid, sodi-
um saccharin, diallyl phthalate, and possibly ethyl
acrylate have been shown to induce cancers in the
forestomach of the rat. Experimental studies with
BHA have shown a correlation between levels in the
diet that induce inflammation and hyperplasia of the
forestomach epithelium and those that cause tumors
(76). At high levels in the diet (2%), BHA induced both
papillomas and carcinomas of the forestomach. Lower
levels (0.5%) were noncarcinogenic by themselves, but
were found to induce hyperplasia and promote fore-
stomach carcinomas initiated with N-methyl-N'-
nitrosoguanidine (NMNG) (77).
Other data, however, raise questions concerning the
mechanism(s) by which BHA and other chemicals act
as promoters in the rat forestomach. Wada et al. (78)
have reported preliminary evidence suggesting that all
chemicals that produce forestomach hyperplasia are
not capable ofpromoting neoplasia. They reported that
p-methoxyphenol (PMP) administered in the diet
induced a strong hyperplastic response in the rat
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forestomach, but failed to promote NMNG-initiated
tumors. The authors suggested that PMP may
adversely affect the carcinogenic process through its
cytotoxic effects, induce the "wrong type" ofhyperpla-
sia, or that PMP metabolites may be anticarcinogens
(78).
Another interpretation of the results of Wada et al.
(78) is suggested by the observations of Rodriguez et
al. (79), who found diverse responses of the rat fore-
stomach to various phenols and acids. It was observed
that while BHA affected the prefundic area of the
forestomach, PMP had its principle effect on the cells
in the midregion. Thus, PMP's proliferative effects
may not be directed at the DEN-initiated cells in the
prefundic area that were most at risk for neoplastic
transformation. The independence of genotoxic and
cytotoxic effects has been evidenced with other chemi-
cal carcinogens.
Proliferative and genotoxic effects in different cell
populations in the same tissue have emerged as an
important factor determining tumorigenic responses to
4-(N-methyl-N-nitrosamino)-1-(2-pyridyl)-1-butanone
(NNK) in rats. NNK is a major carcinogen found in
tobacco products and has produced a high incidence of
tumors in the nasal cavity, liver, and lungs ofrats (80).
In both the liver and nasal cavity, marked increases in
cell proliferation due to cytotoxic effects of NNK dra-
matically affect tumor formation (81). In the nasal cavi-
ty, susceptibility to the genotoxic and cytotoxic effects
of NNK varies considerably between cells located in
the respiratory and olfactory mucosa. Low doses of
NNK that do not produce toxic effects in the nasal
cavity preferentially damage DNA in cells located in
the respiratory mucosa. Thus, at low doses one would
predict these cells to be at greatest risk of cancer. At
high doses the amount of genotoxic damage produced
by NNK was similar in both the olfactory and respira-
tory mucosa, but the olfactory region suffered the
greatest cytotoxic effect. Proliferative changes with
cellular transformation and progression to neoplasia
were most prevalent in the olfactory region coincident
with cytotoxic damage. Therefore, in the nasal cavity,
toxic effects that produced a marked increased in cell
proliferation dramatically affected tumor incidence in
cells at similar risk for genetic damage. Belinsky et al.
(80) speculated that the steep dose-response curve for
induction oftumors by NNK as well as the localization
of tumors can be explained by the difference in sensi-
tivity to its cytoxicity. At low doses the greatest rela-
tive risk of cancer was shifted from cells that were
most sensitive to NNK's cytotoxic effects to those
most sensitive to its genotoxic effects. Such a relation-
ship would not be predicted ifonly the genotoxic effect
of NNK on the respiratory and olfactory mucosa was
considered.
In the rat lung also, the cell type at highest risk for
malignancy from NNK exposure is apparently not that
at greatest risk for genetic damage. The highest level
of DNA adducts in the lungs of NNK-treated rats
occurred in the nonciliated bronchiolar epithelial
(Clara) cells (82). The efficiency of DNA alkylation in
Clara cells by low doses of NNK was 20- to 30-fold
greater than that in type II cells, which are located in
the alveoli. This would seem to make the Clara cell a
sensitive target for neoplastic transformation.
Histologic evidence indicates, however, that benign
and malignant tumors develop from type II cells that
undergo hyperplasia in response to NNK. Interest-
ingly, both hyperplasia and neoplasia in lung tissue
occurred in the absence of any apparent cytotoxic
effects (83), so routine histologic studies would not
have detected any toxic effects in the target cells that
would signal concern. The biological basis for the pro-
liferative response of type II cells is unknown. The
authors speculated that growth signals for type II cells
may originate from the Clara cells that suffer the
greatest damage but are unable to proliferate.
There is at least one reported case in which
increased cell division does not appear to account for
enhanced tumor formation. Administration of butylat-
ed hydroxytoluene (BHT) promotes 3-methylcholan-
threne-initiated lung tumors in A/J strain mice (84). It
was originally assumed that BHT's ability to cause
repeated rounds of cell proliferation in lung alveolar
cell was responsible for its promoting effect. Witschi
(85), however, provided evidence to the contrary. He
demonstrated that BHT's proliferative effect, but not
its ability to enhance lung tumorigenesis, was depen-
dent on its metabolism by mixed-function oxidases.
Inhibitors of these enzymes or other treatments that
prevented BHT's metabolism reportedly eliminated its
proliferative effects on lung tissue, but had no effect on
its ability to promote previously initiated cells in the
lung (85). The exact basis of BHT's promoting effect is
unknown. As in the case ofPB, it is possible that BHT
affects apoptosis of initiated lung cells or has other
effects on specific cell types that were not apparent in
Witschi's experiments.
The studies just described provide several examples
of the complex relationships between genotoxic and
cytotoxic effects in different cell types within the same
tissues. These findings lend some support to the views
by Ames and Gold (3,10) that mitogenesis can domi-
nate chemical carcinogenesis at high doses. At the
same time, however, they caution against making
mechanistic assumptions solely on the basis of cellular
dynamics. For the moment, there is little evidence that
mitogenesis can be exclusively responsible for malig-
nancy. Tumors most likely arise from the collaboration
of genotoxic and non-genotoxic effects. Histopatho-
logical analyses of rodent bioassays have not uncov-
ered any general relationships between cytoxicity,
resultant cell proliferation, and carcinogenic effects
(86). These findings are limited by the absence of a
direct measure of cell division and the restriction of
histopathological data to the end of the bioassay stud-
ies. Nonetheless, most investigators have not been
able to conclude that increased cell proliferation invari-
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ably leads to increased cancer risk. It seems likely that
although additional histopathological studies will con-
tinue to uncover such relationships, they will not be
sufficient to justify mechanistic assumptions that can
be prudently used forassessing human health risks.
Risk Assessment
Assessment of cancer risk to humans from chemical
exposure should include consideration of the multiple
biological factors that influence the carcinogenic
process. In various circumstances, either a chemical's
genotoxic effects or its ability to cause cell prolifera-
tion may limit the rate of neoplastic development. In
order to integrate these concepts and formulate more
biologically based health risk assessments, more than
descriptive studies are required. We need to develop a
better understanding of the molecular mechanisms of
proliferative responses and their consequences for car-
cinogenesis. Without such information it is doubtful
that a coherent understanding of the carcinogenic
process will emerge.
What data will be needed to formulate models that
better reflect the collaboration between genetic dam-
age and cell proliferation in chemical carcinogenesis?
First of all, knowledge of the mechanisms governing
the regulation of growth factors, their receptors, and
how growth factor-receptor interactions determine
proliferative responses to cytotoxicity will be essen-
tial. Findings from in vitro studies point the way to
important parameters that determine the intensity of
proliferative responses. These include the duration of
interaction between a growth factor and its receptor,
and the number of such interactions that occur on the
cell's surface-the latter depending both on the affini-
ty ofthe growth factor forthe receptor and the factor's
concentration in the cell's environment (87). In vivo,
these limiting conditions may be determined by the
amount of cell damage and/or the intensity of inflam-
matory response. The potential of chemically induced
cellular damage to orchestrate these responses is not
well understood. The fact that proliferative responses
are receptor-mediated suggests that dose-response
relationships for proliferative responses are different
than those for cytotoxicity. This raises the prospect
that the cytotoxic effects ofmany chemicals are irrele-
vant for tumor formation at low doses-a prospect for
which NNKprovides agood example.
Second, we need a better understanding of how the
dynamics of cell proliferation and death affect the car-
cinogenic process in vivo. The process of apoptosis
remains mysterious, with only fragmentary informa-
tion on how chemicals influence the normal rate of cell
death in various tissues. Nonetheless, there are rea-
sons to believe that apoptosis has a major role in the
evolution ofpreneoplastic foci in rodent liver. For the
moment, most rapid progress can be made studying
proliferative responses because many clues about their
mechanisms are already available. We should not, how-
ever, neglect these other complexities that are likely
to provide explanations for more provocative results.
The ultimate goal of research should be to establish
biologically based models for tumor development at the
molecular level. This goal is a distant one because it
requires much information not currently available. A
reasonable intermediate goal is to develop cellular mod-
els that incorporate a better understanding of the cir-
cumstances under which various patterns of cell prolif-
eration can influence tumor formation. Biologically
based mathematical models ofthe cancer process have
been developed that incorporate both genotoxic effects
and cell proliferation. The Moolgavkar-Venzon-
Knudson (MVK) two-stage growth model of cancer
(and various modifications of it) has been able to
describe nonlinear tumorigenic responses observed in
rodent bioassays for several chemicals (88-91). The cell
kinetic parameters required for these models are not
easily obtained. Current models require information on
the rates ofgrowth and death of normal and premalig-
nant cells, and the influence of chemicals on these
rates. It may prove difficult, however, to identify the
cell populations most relevant to the tumorigenic
process. In the liver various chemical carcinogens pro-
duce several types of histologically distinct foci. There
is a general consensus that some of these foci are pre-
neoplastic, although it is not precisely clear which ones.
Consequently, there is confusion as to what growth
parameters should be used in mathematical models of
liver carcinogenesis because various foci display differ-
ent growth rates. The puzzle ofwhich cells are most at
risk for progression to malignancy is not unique to the
liver. At present, we can only infer which phenotypi-
cally altered cells will be the first to complete the pro-
tracted sequence ofevents that lead to cancer.
There are several important ways that these mathe-
matical models can help us understand various aspects
of the cancer process. Refinement of current mathe-
matical models of carcinogenesis that incorporate
chemically induced cell proliferation will point to key
areas for further molecular investigations. In addition,
pursuit of the molecular basis of a cell's proliferative
response to chemicals will contribute to a better
understanding of the bases of species sensitivity and
tissue specificity in chemical carcinogenesis. Cohen
and Ellwein (26), in their recent article on the conse-
quences of chemically induced cell proliferation in can-
cer, summarized their views on the role ofmathemati-
cal models as follows:
It should be obvious that the real contribution ofmodeling
is enhanced insight, not numbers. In terms of human risk
assessment, the existence ofa non-effect threshold, for exam-
ple, cannot be ruled in or out on the basis of model analyses.
Only experimental mechanism studies can provide the infor-
mation base necessary to predict biological response disconti-
nuities between high- and low-dose response.
This is a good perspective to keep in mind. More
sophisticated mathematical models are unlikely to pro-
vide certain evidence on which to base regulatory deci-
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sions. They can, however, be used to distinguish the
plausible from the implausible and in that way provide
valuable guidance for regulatory decisions and setting
research priorities.
Experimental results for several chemicals provide
strong support for regulatory decisions based on evi-
dence of their ability to stimulate cell proliferation.
For example, kidney tumors induced by chemicals that
cause a-2g-globulin nephropathy, bladder tumors
induced by melamaine and saccharin, and thyroid-stim-
ulating hormone-mediated thyroid tumors. Although
there are currently a small number of such cases, they
illustrate the use of such information to craft a more
rational basis for regulatory decisions. In the absence
of sound data, however, it is reasonable to continue to
use conservative assumptions in estimating health
risks.
Summary and Recommendations
I have briefly discussed the role of cell proliferation
in various stages ofthe cancer process and some ofthe
evidence that chemicals that cause a sustained increase
in the rate of cell division in tissues can increase the
risk of cancer. Subjects touched on in this review have
received more authoritative treatments elsewhere. The
objective ofthis review has been to point out the com-
plexity ofthe proliferative responses in various tissues
exposed to chemicals and that uncertainties exist as to
their exact relation to tumor formation.
The risk of neoplastic disease can be magnified by
increases in genotoxicity or the rate of cell division.
While there is general agreement among scientists
that both cell proliferation and genetic damage are key
factors that affect cancer risk, there is disagreement
over their relative importance in assessing the risk to
human health from exposure to various chemicals
shown to cause cancer in rodents. This is particularly
true for non-DNA-reactive chemicals as to whether
they exhibit a no-effect level if they act exclusively
through their cytotoxic and/orproliferative effects.
Renewed appreciation that chemically induced cell
proliferation can contribute substantially to the risk of
malignant transformation presents an opportunity for
a more complete and accurate understanding of the
carcinogenic process and the health risks to humans
from chemical exposures. Clearly, a chemical's poten-
tial to produce cytotoxic effects and induce sustained
cell proliferation are factors that can significantly
affect the shape of the dose-response curve for malig-
nant transformation. The potential consequence of
increased cell division in tissues exposed to high doses
of chemical carcinogens is an increased estimate of
cancer potency that would seem inappropriate for
assessing cancer risk from low-level exposures where
increased cell proliferation does not occur.
The absence ofcell proliferation at low doses, howev-
er, should not be equated with the absence of health
risk. Chemicals with genotoxic effects may still cause
genetic damage even at low doses and nongenotoxic
chemicals can affect cell populations in subtle ways
such as by preventing apoptosis. Furthermore, because
of the complexities of human chemical exposure, it is
unrealistic to presume that the consequences ofgenet-
ic damage from low doses of a chemical are irrelevant
because they are insufficient to produce other effects.
It may be difficult, however, to resolve when and
how different patterns of chemically induced cell pro-
liferation influence tumor formation. Few dose-
response relationships for both cell proliferation and
tumorigenesis have been examined for chemical car-
cinogens at doses much lower than those customarily
used in rodent bioassays. Thus, most views concerning
the contribution ofchemically induced cell proliferation
to tumor formation are based on results of a few stud-
ies for which contradictory evidence exists. In the
absence of knowledge at the molecular level of how
chemicals influence cell growth and how distinct
growth patterns affect various stages of the cancer
process, it will be difficult to accurately assess the rela-
tive contributions ofgenotoxic and proliferative effects
on the cancer process and predict how they will vary
with dose.
Although descriptive rodent bioassays could conceiv-
ably solve this problem, the expense of such studies is
prohibitive. Furthermore, descriptive studies would
not resolve the uncertainties inherent in interspecies
extrapolation, a major reason for uncertainty when
human risk assessments are based on rodent bioassay
data. As we gain a better understanding of many fun-
damentals of the cancer process, we can envision key
pieces ofthe puzzle that will enable us to better assess
cancer risk to humans posed by chemicals in the envi-
ronment. Future research that concentrates on under-
standing the basic molecular mechanisms by which tis-
sues control their size and shape and how they respond
and adapt to chemical injury will provide this essential
information.
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